A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Control Subjects.
Phase of Trial: Phase I
Latest Information Update: 01 Jan 2017
At a glance
- Drugs Siponimod (Primary)
- Indications Dermatomyositis; Multiple sclerosis; Polymyositis
- Focus Pharmacokinetics
- Sponsors Novartis; Novartis Pharmaceuticals
- 25 Apr 2015 Results presented at the 67th Annual Meeting of the American Academy of Neurology.
- 13 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 17 Jan 2014 According to the ClinicalTrials.gov record, Planned End Date changed from 1 Jan 2014 to 1 Mar 2014.